Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

by B2i | Apr 28, 2022 | Press Releases

JUPITER, Fla., April 28, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...

Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform

by B2i | Apr 13, 2022 | Press Releases

India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to support Phase 1 and 2 clinical trials of Epygen’s COVID-19 vaccine candidateDyadic’s C1 protein...

Dyadic International to Present at Upcoming Scientific Medical Meetings

by B2i | Apr 4, 2022 | Press Releases

JUPITER, Fla., April 04, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform...

Dyadic Reports 2021 Year End Results and Recent Company Progress

by B2i | Mar 29, 2022 | Press Releases

New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of $690,000 under the White House’s American Rescue PlanNew license agreement with Phibro Animal Health to...

Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022

by B2i | Mar 15, 2022 | Press Releases

JUPITER, Fla., March 15, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...